ScholarLens Back to search
2015•Unpublished venueOpen access

Four-factor prothrombin complex concentrate (4F-PCC) reverses bleeding associated with the new direct oral anticoagulants (NOACs) dabigatran, rivaroxaban, edoxaban and apixaban in a rabbit model

Eva Herzog, Franz Kaspereit, Wilfried Krege, Jochen Mueller‐Cohrs, Baerbel Doerr, Peter Niebl, Gerhard Dickneite

Open full text 0 citations

Abstract

Background: To summarize the efficacy of the non-activated four-factor PCC (4F-PCC) *Beriplex®/Kcentra® (CSL Behring) in controlling acute NOAC-associated bleeding in an in vivo rabbit model. To evaluate correlations between in vivo measures of haemostasis and in vitro coagulation parameters. Main conclusions: In this rabbit model of acute haemorrhage 4F-PCC, administered at a clinically relevant dose range, showed potential for reversing NOAC-associated bleeding for all NOACs tested, including direct FIIa inhibitor dabigatran, and FXa inhibitors edoxaban, rivaroxaban and apixaban. These data suggest that 4F-PCC may be an option for the urgent reversal of the anticoagulant effect of NOACs. Further clinical data in human patients are required to confirm these results.

About this research paper

What this paper is about

Background: To summarize the efficacy of the non-activated four-factor PCC (4F-PCC) *Beriplex®/Kcentra® (CSL Behring) in controlling acute NOAC-associated bleeding in an in vivo rabbit model. To evaluate correlations between in vivo measures of haemostasis and in vitro coagulation parameters. Main conclusions: In this rabbit model of acute haemorrhage 4F-PCC, administered at a clinically relevant dose range, showed potential for reversing NOAC-associated bleeding for all NOACs tested, including direct FIIa inhibitor dabigatran, and FXa inhibitors edoxaban, rivaroxaban and apixaban. These data suggest that 4F-PCC may be an option for the urgent reversal of the anticoagulant effect of NOACs. Further clinical data in human patients are required to confirm these results.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Background: To summarize the efficacy of the non-activated four-factor PCC (4F-PCC) *Beriplex®/Kcentra® (CSL Behring) in controlling acute NOAC-associated bleeding in an in vivo rabbit model. To evaluate correlations between in vivo measures of haemostasis and in vitro coagulation parameters. Main conclusions: In this rabbit model of acute haemorrhage 4F-PCC, administered at a clinically relevant dose range, showed potential for reversing NOAC-associated bleeding for all NOACs tested, including direct FIIa inhibitor dabigatran, and FXa inhibitors edoxaban, rivaroxaban and apixaban. These data suggest that 4F-PCC may be an option for the urgent reversal of the anticoagulant effect of NOACs. Further clinical data in human patients are required to confirm these results.

Key concepts: Edoxaban, Rivaroxaban, Dabigatran, Apixaban, Medicine, Open peer review, Pharmacology, Plant biology

Back to paper searchBrowse research topicsOriginal source
Four-factor prothrombin complex concentrate (4F-PCC) reverses bleeding associated with the new direct oral anticoagulants (NOACs) dabigatran, rivaroxaban, edoxaban and apixaban in a rabbit model — Research Paper | ScholarLens